US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Results of the Annual General Meeting

Faron Pharmaceuticals Oy ("Faron" or the "Company") Results of the Annual General Meeting and Decisions of the Board of Directors Company announcement, 18 May 2020 at 6 pm (EEST) TURKU, FINLAND - The annual general meeting ("AGM") of Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON) took place in Turku, Finland today, 18 May 2020. The AGM approved all the proposals of the board of directors ("Board") and its committees set out in the notice of the AGM published on 14 April 2020. Due to the current COVID-19 situation, strict precautionary measures were taken to ensure

Exercise of options

Faron Pharmaceuticals Oy                    ("Faron" or the "Company") Exercise of options Issue of equity Company announcement, 13 May 2020 at 15.00 (EEST) TURKU, FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces that it has received notifications from option holders to exercise D options over 9,000 ordinary shares in the Company at an exercise price of €1.09 per share under the Company's 2015 Option Plan ("New Ordinary Shares"). The terms and conditions of the 2015 Option Plan are available on the

Managers’ transactions

Faron Pharmaceuticals Oy                      ("Faron" or the "Company") Managers' transactions Company announcement, 12 May 2020 at 8 PM (EEST) TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that Mr Toni Hänninen, Chief Financial Officer of the Company, acquired 3,500 ordinary shares in Faron at a price of €4.3255 per share on 12 May 2020. Following these purchases, Mr Hänninen holds 50,297 ordinary shares in the Company. The notification below, which has been made in accordance with

Faron receives grant from Business Finland

Faron Pharmaceuticals Oy ("Faron" or the "Company") Faron receives €800,000 grant from Business Finland as part of Cancer IO, Finland's leading Personalized Health Program -      Grant will enable state-of-the-art characterization of immunological responses in MATINS trial-      Clevegen to be studied in experimental combinations with anti-cancer molecules from other consortium members   Company announcement, 11 May 2020 at 12.00 PM (EET)Inside information TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical

Clevegen manufacturing agreement

Faron Pharmaceuticals Oy("Faron" or the "Company")  Faron contracts with AGC Biologics in commercial scale Clevegen manufacturing agreement  Company announcement, 05 May 2020 at 9.00 AM (EEST)Inside informationTURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that global contract development and manufacturing organisation AGC Biologics has been selected to be the commercial scale manufacturer of Clevegen, Faron's wholly-owned novel precision cancer immunotherapy targeting Clever-1 positive

Holding(s) in Company

TR-1: Standard form for notification of major holdings [][][][][][][]NOTIFICATION OFMAJOR HOLDINGS(to besent to the relevantissuer and tothe FCA in MicrosoftWord format ifpossible)[i] 1a. Identity of the Faron Pharmaceuticalsissuer or theunderlying issuer ofexisting sharesto which votingrights areattached[ii]:1b. Please indicateif the issuer isa non-UKissuer  (please markwithan "X" ifappropriate)Non-UK issuer X2. Reason for thenotification (pleasemark the

Traumakine to be a part of WHO’s Solidarity trial

Faron Pharmaceuticals Oy("Faron" or the "Company") Traumakine to be a part of WHO's Solidarity trial investigating potential COVID-19 treatments Company announcement, 27 April 2020 at 9.00 AM (EEST)Inside information TURKU, FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that the Company will donate supplies of its investigational intravenous (IV) interferon (IFN) beta-1a for 2,000 patients in the World Health Organization's (WHO) Solidarity trial investigating potential COVID-19 treatments.

Update on results of Placing and issue of equity

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, SINGAPORE, HONG KONG OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Faron Pharmaceuticals Oy Update on results of Placing and Issue of Equity Capitalised terms used in this announcement have the meanings given to them in the announcement made at 4.45 p.m. BST/ 6.45 p.m.

Result of placing and issue price

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, SINGAPORE, HONG KONG OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Faron Pharmaceuticals Oy   Result of Placing and Issue Price and Broker Option Capitalised terms used in this announcement have the meanings given to them in the announcement made at 4.45 p.m. BST/ 6.45

Proposed Placing

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, SINGAPORE, HONG KONG OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE EU REGULATION 596/2014. MEMBERS OF THE PUBLIC ARE NOT ELIGIBLE TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN

Notice of Annual General Meeting

NOTICE OF FARON PHARMACEUTICALS LTD'S ANNUAL GENERAL MEETING Shareholders of Faron Pharmaceuticals Ltd (the "Company") are notified of the annual general meeting (the "AGM") to be held on 18 May 2020 at 10:00 a.m. (Finnish time) at the offices of the Company at Joukahaisenkatu 6, 20520 Turku, Finland. The registration of attendees and the distribution of voting slips will commence at the meeting venue at 9:00 a.m. (Finnish time). Due to the SARS-CoV-2 situation, the AGM will only be held if the number of participants at the meeting is low enough to allow the AGM to be conducted safely

AGM to be postponed

Faron Pharmaceuticals Oy ("Faron" or the "Company") AGM to be postponed Company announcement, 3 April 2020 at 4.45pm (EEST) TURKU, FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces that, due to the prevailing Covid-19 situation, the Company's Board of Directors has decided to cancel the Company's annual general meeting ("AGM") scheduled to be held on 15 April 2020.   A new notice will be published in due course to convene the AGM at a later stage. For more information please contact:

REMAP-CAP to study IFN beta-1a effect in COVID-19

Faron Pharmaceuticals Oy                ("Faron" or the "Company") Global Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) to study the effect of interferon beta-1a in COVID-19   Company announcement, 1 April 2020 at 9.00 AM (EEST)Inside information TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that regulatory approval has been granted for the global Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-

Part 1 of the MATINS Phase I/II Study Completed

Faron Pharmaceuticals Oy                      ("Faron" or the "Company") Completion of Part 1 dose finding stage of the MATINS Phase I/II Study Study data monitoring committee recommends rapid expansion of study into new tumour types following promising results Company announcement, 30 March 2020 at 9.00 AM (EET)Inside information TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces positive feedback from the MATINS study data monitoring committee ("DMC") following a comprehensive review

Correction to Faron´s Annual Report 2019

Faron Pharmaceuticals Oy ("Faron" or the "Company")   Correction to Faron´s Annual Report 2019       Company announcement, 26 March 2020 at 12.00 PM (EET)    TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces the correction to the Annual Report 2019 which has been published yesterday.   The correction is related to the average number of shares and EPS (loss per share). The correct average number of shares is 36,850,577 not 35,533,179 in 2019 as published earlier yesterday in the

Faron´s Annual Report 2019 published

Faron Pharmaceuticals Oy ("Faron" or the "Company")   Faron´s Annual Report 2019 published     Company announcement, 25 March 2020 at 9.00 AM (EET)    TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces that its Annual Report for the year 2019 has been published today.   Faron Pharmaceuticals´ Annual Report 2019 and financial statements for the accounting period 1 January - 31 December 2019 have been published in English and its financial statements in Finnish, on the Company's

Notice of Annual General Meeting

NOTICE OF FARON PHARMACEUTICALS LTD'S ANNUAL GENERAL MEETING Company announcement, 20 March 2020 at 1.30 PM (EET) Shareholders of Faron Pharmaceuticals Ltd (the "Company") are notified of the annual general meeting (the "AGM") to be held on 15 April 2020 at 2:00 p.m. (Finnish time) at the BioCity building, meeting room Manu at Tykistökatu 6, 20520 Turku, Finland. The registration of attendees and the distribution of voting slips will commence at the meeting venue at 1:00 p.m. (Finnish time). Due to the prevailing SARS-CoV-2 situation, the Company encourages its shareholders to

Final Results for the year ended December 31, 2019

Faron Pharmaceuticals Oy ("Faron" or the "Company")   Financial statement release January 1 to December 31, 2019   Financial statement release, Turku, 20 March 2019 at 9.00 AM (EET) Inside information   TURKU, FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today reports its financial statements for the year ended 31 December 2019 and H2 2019.   HIGHLIGHTS   Operational (including post period):   Clevegen[®] - Regulator of major inhibitory immune checkpoints and wholly-owned novel

FDA accepts protocol for new Traumakine trial

Faron Pharmaceuticals Oy ("Faron" or the "Company")   FDA accepts protocol for new Traumakine trial in ARDS       Company announcement, 09 March 2020 at 9.00 AM (EET)Inside information   TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces that the U.S. Food and Drug Administration (FDA) has accepted the proposed protocol design for the next Traumakine study in ARDS patients, following the Company's protocol submission announced on 6 February 2020.    The trial protocol

MATINS update

Faron Pharmaceuticals Oy ("Faron" or the "Company")   MATINS update Second tumour regression identified, now in a melanoma patient   Company announcement, 05 March 2020 at 9.00 AM (EET)Inside information   TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces that in the ongoing dose finding part of the MATINS trial (Part I) a partial response has been identified in target lesions of a melanoma patient who has previously been heavily treated with immuno-oncology ("IO") and chemo therapies.

Faron to acquire AOC3 antagonist platform

Faron Pharmaceuticals Oy ("Faron" or the "Company") Faron to acquire AOC3 antagonist platform technology   Company announcement, 02 March 2020 at 9.00 AM (EET)Inside information   TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces that it has acquired rights for the potential new use of AOC3 inhibitors ("Agreement") covered by a recently filed patent application ("Invention"). The AOC3 enzymatic domain, a semicarbazide-sensitive amine oxidase is known to produce hydrogen peroxide, a

Traumakine update

Faron Pharmaceuticals Oy ("Faron" or the "Company")   Traumakine update  -     New trial protocol preventing concomitant corticosteroid use with Traumakine -     Company notes WHO recommendations on use of steroids in coronavirus patients   Company announcement, 06 February 2020 at 9.00 AM (EET)Inside information TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today provides an update on Traumakine's clinical continuation following a meeting with the U.S. Food and Drug Administration (FDA) in

There are no items matching the current filter
There are no more items matching the current filter
Back to top